Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06215586 · ClinicalTrials.gov registry record · Phase 2
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT06215586: Completed Phase 2 study, sponsored by Cardurion Pharmaceuticals.
NCT06215586 is a Phase 2 study that has completed, run by Cardurion Pharmaceuticals. The registered enrollment target is 303 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06215586, a Phase 2 study, has completed, sponsored by Cardurion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Primary Outcome
The percent change in plasma NT-proBNP from Baseline to Week 12.
Interventions
- DRUG Placebo
- DRUG Tovinontrine (CRD-750
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 2 |
What the finished NCT06215586 record still lists
NCT06215586 is an interventional study that assigns participants to a tested intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06215586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06215586 about?
NCT06215586 is a clinical study titled "Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)". The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
What is the current status of trial NCT06215586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2024-02-13. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT06215586?
The interventions under investigation include: Placebo (DRUG), Tovinontrine (CRD-750 (DRUG).
Who is sponsoring clinical trial NCT06215586?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06215586's enrollment target sits among peer trials
303 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI